BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Treeline Biosciences

1 post

Treeline Biosciences is a biotechnology company founded by Josh Bilenker, M.D. and Jeff Engelman M.D., Ph.D. The name was curated to connote the concept of the outer limits of scientific possibilities, the places where conditions are a challenge but the metaphorical trees and forests still thrive and grow.

Treeline Biosciences is focused on oncology molecular targets that are currently validated but have to date been difficult to successfully drug. Treeline Biosciences believes their unique approach may further be applied to other areas of therapeutics as well.

Former Lilly CEO Josh Bilenker & Former Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

Biotech NewsEx-Lilly CEO Josh Bilenker & Ex-Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

  • BioTech Health X
  • April 30, 2021
Two powerhouse executives have joined forces to form a brand new cancer Biotech company. Josh Bilenker, M.D., and…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Scholar Rock (SRRK): The $3 Billion Biotech You’ve Never Heard Of—But Wall Street Can’t Stop Watching
  • BeOne Medicines (ONC) is Quietly Taking Over the Global Cancer Drug Market
  • Nevro (NVRO) Could Surge Beyond its Buyout Offer in 2025
  • Johnson & Johnson (JNJ) can be the Next Trillion-Dollar Stock
  • Boston Scientific (BSX) Just Signed a $45M Deal—Here’s What It Means for Investors
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • June 8, 2025
    Scholar Rock (SRRK): The $3 Billion Biotech You’ve Never Heard Of—But Wall Street Can’t Stop Watching
    • June 8, 2025
    BeOne Medicines (ONC) is Quietly Taking Over the Global Cancer Drug Market
    • June 8, 2025
    Nevro (NVRO) Could Surge Beyond its Buyout Offer in 2025
    • June 8, 2025
    Johnson & Johnson (JNJ) can be the Next Trillion-Dollar Stock
    • June 8, 2025
    Boston Scientific (BSX) Just Signed a $45M Deal—Here’s What It Means for Investors
Recent Posts
  • Procept BioRobotics (PRCT) is Heating Up — Can it Redefine Robotic Surgery?
    • June 8, 2025
  • This Tiny Surgical Robot Stock Could Disrupt a $30 Billion Industry: Microbot Medical (MBOT)
    • June 8, 2025
  • Pro-Dex (PDEX) Plunges 39% – Here’s Why Smart Investors Are Buying the Dip
    • June 8, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (171)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top